Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on January 14, 2008

Hypertension. 2008
Published online before print January 14, 2008, doi: 10.1161/HYPERTENSIONAHA.107.101634
A more recent version of this article appeared on February 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
51/2/528    most recent
HYPERTENSIONAHA.107.101634v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsukuda, K.
Right arrow Articles by Horiuchi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsukuda, K.
Right arrow Articles by Horiuchi, M.
Related Collections
Right arrow Behavioral/psychosocial - treatment
Right arrow Type 2 diabetes
Right arrow Animal models of human disease

Submitted on October 3, 2007
Revised on October 15, 2007

Diabetes-Associated Cognitive Impairment Is Improved by a Calcium Channel Blocker, Nifedipine

Kana Tsukuda; Masaki Mogi; Jian-Mei Li; Jun Iwanami; Li-Juan Min; Akiko Sakata; Teppei Fujita; Masaru Iwai; and Masatsugu Horiuchi*

From the Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine, Ehime, Japan.

* To whom correspondence should be addressed. E-mail: horiuchi{at}m.ehime-u.ac.jp.

Abstract—Nifedipine, a calcium channel blocker, has been reported to exert pleiotropic effects on atherosclerosis, mainly through its antioxidative properties. However, the effect of the calcium channel blocker on cognitive impairment associated with type 2 diabetes mellitus is not well known. Here, we examined the possibility that a calcium channel blocker could improve cognitive function in a type 2 diabetic mouse model, KK-Ay. KK-Ay mice subjected to 20 trials of a passive avoidance task every week from 7 weeks of age exhibited impairment of the increase in avoidance rate and, moreover, exaggeration of its age-dependent decline, especially after 12 weeks of age. Oral administration of nifedipine at a nonhypotensive dose (0.001% in laboratory chow) to KK-Ay mice from 10 weeks of age improved cognitive function. Nifedipine treatment decreased serum insulin level to one fifth of that in KK-Ay mice without nifedipine. Moreover, nifedipine treatment significantly reduced superoxide anion production in the brain. Furthermore, treatment with nifedipine markedly reduced the mRNA level of Id-1, inhibitor of neural differentiation, in the brain hippocampus. We also observed the increase in blood flow in the brain in KK-Ay mice with nifedipine treatment compared with nontreated mice. Taken together, our findings suggest that nifedipine ameliorates impaired cognitive function in type 2 diabetic mice, at least because of attenuation of hyperinsulinemia and superoxide production in the brain and possible upregulation of the neural differentiation-controlling gene, Id-1.


Key words: diabetes mellitus • cognitive impairment • calcium channel blocker • oxidative stress • neural differentiation